Mangoceuticals financials
$0.4445+15.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 | Q2 '23 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.9K | $94.4K | $84.2K | $168.1K | $109.3K | $105.2K | $133.4K | $163.2K | $214.1K | $244.4K | $245.2K | $141.2K |
| Gross profit | $59.6K | $47.5K | $50.9K | $89.9K | $84.6K | $80.1K | $82.7K | $69.8K | $147.4K | $45.9K | $193.0K | $115.6K |
| Gross margin | 87.9% | 50.3% | 60.4% | 53.5% | 77.4% | 76.1% | 62.0% | 42.8% | 68.8% | 18.8% | 78.7% | 81.9% |
| Operating income | -$1.8M | -$1.6M | -$7.5M | -$5.3M | -$3.8M | -$1.9M | -$2.0M | -$2.2M | -$2.4M | -$2.6M | -$1.8M | -$2.3M |
| Net income | -$3.7M | -$3.1M | -$7.9M | -$5.4M | -$5.1M | -$1.9M | -$2.3M | -$2.4M | -$2.4M | -$2.6M | -$1.8M | -$2.3M |
| Net margin | −5447.9% | −3246.7% | −9391.8% | −3221.6% | −4696.3% | −1851.2% | −1719.5% | −1465.4% | −1105.9% | −1050.9% | −734.0% | −1617.2% |
| Diluted EPS | $-0.22 | $-0.21 | $-0.69 | $-0.57 | $-1.12 | $-0.75 | $-1.14 | $-1.37 | $-1.50 | $-1.06 | $-1.70 | $-2.10 |
| EBITDA | -$1.5M | -$1.0M | -$7.5M | -$4.4M | -$3.4M | -$1.2M | -$2.0M | -$2.1M | -$2.4M | -$2.6M | -$1.8M | -$2.3M |
| Operating cash flow | -$1.3M | -$1.1M | -$1.2M | -$1.3M | -$2.3M | -$1.1M | -$1.2M | -$1.6M | -$991.1K | -$1.7M | -$1.7M | -$1.8M |
| Free cash flow | -$1.3M | -$1.1M | -$1.2M | -$1.3M | -$2.3M | -$1.1M | -$1.2M | -$1.6M | -$991.1K | -$1.7M | -$1.7M | -$1.8M |
| Diluted shares | 16.5M | 14.7M | 11.5M | 9.5M | 4.6M | 2.6M | 2.0M | 1.7M | 1.6M | 2.4M | 1.1M | 1.1M |
Balance sheet
| Period end | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $174.6K | $1.5M | $481.3K | $101.0K | $76.5K | $58.7K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $100.0K | $500.0K | $0.00 | $150.0K |
| Total assets | $14.4M | $16.1M | $16.5M | $20.8M | $21.8M | $15.4M |
| Total liabilities | $974.6K | $890.6K | $804.3K | $1.6M | $1.5M | $1.4M |
| Shareholders' equity | $13.5M | $15.2M | $15.7M | $19.2M | $20.3M | $13.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology